Nordicus Partners Corp
Close on Oct 19, 2026
- Market cap
- $77.44M
- P/E (TTM)
- –
- Dividend yield
- –
About Nordicus Partners
Services-Management Consulting Services, SIC 8742
Nordicus Partners Corporation is a biotechnology firm that acquires and develops early-stage drug candidates focusing on inflammation and immune modulation. Its portfolio includes three preclinical research subsidiaries developing treatments for patients with oral disorders and inflammatory skin conditions. Orocidin A/S develops QR-01, an oral formulation for aggressive periodontitis. Bio-Convert A/S develops QR-02, a mucoadhesive oral gel for oral leukoplakia lesions. NoviThera ApS develops QR-04, a monoclonal antibody treatment for psoriasis. In addition, the firm holds a minority interest in a commercial real estate mortgage banking business.
The company is based in Beverly Hills, California, and conducts business in the United States and Denmark. Its operational footprint comprises subsidiaries in Denmark, research partnerships with the University of Copenhagen, and good manufacturing practice production located in Germany. The entity owns no real estate properties.
Summary of the business section of Nordicus Partners's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nordicus Partners Corp
- Founded
- 1993
- Headquarters
- Beverly Hills, CA
- Address
- 280 South Beverly Dr., Suite 505 90212
- Phone
- (508) 523-3141
- Industry
- Services-Management Consulting Services
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- Fruci & Associates II, PLLC, Spokane, Washington
Stock & identifiers
- Ticker
- NORD
- Exchange
- OTC
- IPO date
- Jun 12, 1996
- Shares outstanding
- 19M, Sep 21, 2026
- Public float
- $21.13M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Nov 14, 2024; 1-for-10 reverse, Nov 8, 2024; 1-for-50 reverse, Jun 28, 2022; 1-for-50 reverse, Mar 11, 2022
- SEC CIK
- 1011060
- CUSIP
- 28265K205
- ISIN
- US28265K2050
- LEI
- 5493003R8IZLC8FAEP28
- EIN
- 04-3186647
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Bennett J. Yankowitz | Chief Financial Officer, Director | – |
| Henrik Rouf | Chief Executive Officer | 950,991 |
| Henrik Keller | Director | – |
| Bach Peter Severin | Director | – |
Corporate history
Events identified from SEC filings